These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 17347926)

  • 1. [Susceptibility to strategy of the drug component of the IPHCC+RxGroups classification system in a risk-adjusted morbidity compensation scheme--a conceptional and data-supported analysis].
    Behrend C; Felder S; Busse R
    Gesundheitswesen; 2007 Jan; 69(1):1-10. PubMed ID: 17347926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Options for a future risc structure compensation in Germany].
    Greiner W
    Gesundheitswesen; 2006 Jul; 68(7):442-8. PubMed ID: 16868871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of health care utilization by German sickness fund members--with application to risk adjustment.
    Breyer F; Heineck M; Lorenz N
    Health Econ; 2003 May; 12(5):367-76. PubMed ID: 12720254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal health insurance and high-risk groups in West Germany: implications for U.S. health policy.
    Wysong JA; Abel T
    Milbank Q; 1990; 68(4):527-60. PubMed ID: 2292990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk structure compensation in Germany's statutory health insurance.
    Busse R
    Eur J Public Health; 2001 Jun; 11(2):174-7. PubMed ID: 11420805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk selection in the German public health insurance system.
    Nuscheler R; Knaus T
    Health Econ; 2005 Dec; 14(12):1253-71. PubMed ID: 15942977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Switching sickness funds and risk compensation mechanisms in the statutory health insurance system in Germany--empirical results from the cooperative health research in the region of Augsburg (KORA)].
    Werner A; Reitmeir P; John J
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S158-66. PubMed ID: 16032535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Towards the inclusion of health state in the Israeli risk-adjustment scheme using medical diagnoses--some intermediate results].
    Shmueli A; Haklai Z; Gordon ES
    Harefuah; 2005 Mar; 144(3):173-7, 231. PubMed ID: 15844455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of selection inventives for health insurances after introduction of the morbidity-oriented risk compensation scheme: an empirical analysis].
    Lüngen M; Drabik A; Büscher G; Passon A; Siegel M; Stock S
    Gesundheitswesen; 2010 Nov; 72(11):790-6. PubMed ID: 20104447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of predictive value of four risk models in Medicaid recipients with chronic obstructive pulmonary disease in Texas.
    Yarger S; Rascati K; Lawson K; Barner J; Leslie R
    Clin Ther; 2008; 30 Spec No():1051-7. PubMed ID: 18640479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Notes on the planned German health fund model].
    Robra BP; Mayrhofer T
    Gesundheitswesen; 2006 Oct; 68(10):650-2. PubMed ID: 17099827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Needs for further improvement: risk adjustment in the German health insurance system.
    Buchner F; Wasem J
    Health Policy; 2003 Jul; 65(1):21-35. PubMed ID: 12818743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deriving a risk-adjustment formula for hospital financing: integrating the impact of socio-economic status on length of stay.
    Perelman J; Shmueli A; Closon MC
    Soc Sci Med; 2008 Jan; 66(1):88-98. PubMed ID: 17888552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the additional costs of dispensing workers' compensation prescriptions.
    Schafermeyer KW
    Res Social Adm Pharm; 2007 Mar; 3(1):123-36. PubMed ID: 17350561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative evaluation of methods to determine efficiency potentials in drug utilisation].
    Pfannkuche MS; Hoffmann F; Meyer F; Glaeske G
    Gesundheitswesen; 2007 Dec; 69(12):670-8. PubMed ID: 18181070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior health expenditures and risk sharing with insurers competing on quality.
    Marchand M; Sato M; Schokkaert E
    Rand J Econ; 2003; 34(4):647-69. PubMed ID: 14992229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Haemophilia in the German risk adjustment scheme].
    Ballesteros P
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S65-9. PubMed ID: 21042686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.